As a result, Mylan stock has trended down for four years. Before the second quarter rise, Mylan sales declined year over year for seven consecutive quarters. Mylan earnings also fell seven of the last nine quarters. SVB Leerink analyst Ami Fadia sees hope in Pfizer's willingness to jump in.